Navidea Biopharmaceuticals (NYSE:NAVB) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of Navidea Biopharmaceuticals (NYSE:NAVB) in a research report issued to clients and investors on Sunday. The brokerage set a “sell” rating on the stock.

Navidea Biopharmaceuticals Stock Performance

Navidea Biopharmaceuticals stock opened at $0.04 on Friday. Navidea Biopharmaceuticals has a twelve month low of $0.02 and a twelve month high of $0.28. The stock’s fifty day simple moving average is $0.04 and its 200-day simple moving average is $0.05. The firm has a market capitalization of $3.50 million, a P/E ratio of -0.58 and a beta of 1.13.

Institutional Trading of Navidea Biopharmaceuticals

An institutional investor recently raised its position in Navidea Biopharmaceuticals stock. State Street Corp boosted its holdings in Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) by 1,631.1% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 412,743 shares of the company’s stock after buying an additional 388,900 shares during the quarter. State Street Corp owned approximately 1.18% of Navidea Biopharmaceuticals worth $38,000 at the end of the most recent quarter. 0.01% of the stock is currently owned by hedge funds and other institutional investors.

Navidea Biopharmaceuticals Company Profile

Navidea Biopharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.